Bioverge Funds

What an investment in Bioverge Funds offers you.

Simplified Access to Premier Investments

Invest in a healthcare venture capital fund that reduces barriers to institutional-quality assets more efficiently and with low fees.

Invest alongside top-tier venture funds, at the same terms.

Streamlined Diversification

We do the heavy lifting. With a single investment, the Bioverge professionals will build you a diversified portfolio of emerging healthcare investments with unique potential for both outsized investment returns and outsized impact on the world.

Exclusive Access

Bioverge Funds have preferred access to all Bioverge deals, including pro-rata and special one-time opportunities. Fund investors also enjoy discounted fees when participating directly on a deal-by-deal basis.

Get notified when new Bioverge Funds are open for investment

Request Access

Click here to learn more about our flagship fund, the Bioverge Access Fund (now open to investors)

FAQs

What are Bioverge Funds?

Bioverge Funds allow investors to access 15 or more companies via a single investment. Our Bioverge Deal-by-Deal products, by comparison, typically invest in a single deal/company. Diversification is a benefit of the Bioverge Funds, as investment risk may be spread across multiple assets. Additionally, investors in Bioverge Funds can access healthcare venture capital opportunities on a wider scale than they might otherwise be able to by making individual investments.

How does investing work?

Once you create an account, you will be able to review our investment opportunities. Once you’re ready to invest, our platform will prompt you with any questions necessary to complete your investment documents online and how to fund your investments. As an investor, you will have access to your portfolio details and you will receive quarterly updates on how your investments are performing. If an investment exit is realized, you will receive associated distribution income or public shares (refer to the complete set of deal documents for further details).

Can international investors participate?

Yes, international investors can participate in Bioverge Funds. Our offerings are conducted under the SEC's Regulation D, Rule 506, which allows for participation from both domestic and international investors, provided that they are accredited and comply with the regulations of their respective jurisdictions.

How are my investments protected?

Each Bioverge Fund is a limited liability company (LLC) that invests in private securities offerings and is managed by Bioverge. We act as the decision-maker on your behalf, handling the day-to-day operations. As a Bioverge Fund investor, your investment is held in the form of ownership interest in the LLC. If something were to happen to Bioverge (the company), you would still maintain your ownership of the LLC and the entity’s underlying investment holdings.

View All FAQs

Footnotes

1 Data as of March 31, 2023. Returns shown for each Access Fund reflect the fair market value of investments as determined in good faith by Bioverge according to our stated valuation policy (see Investor Disclosure for additional information). Unrealized investments are recorded at cost, and are only re-valued upon consummation of an arms-length transaction, either an Up-round or Down-round in a portfolio company, in accordance with this policy, or written off as a total loss if Bioverge so determines. Up-round generally means a financing subsequent to Bioverge’s investment has occurred at a higher per-share valuation (more favorable) than our original investment. Downround generally means a subsequent financing has occurred at a lower per-share valuation (less favorable) than our original investment. Realized values are based upon an amount received in the event of an Exit (such as an acquisition by an acquirer) or an initial public offering (IPO), or similar proceeds. Exits are based on gross distributions available at the time a transaction closed and include escrows and amounts receivable at a future date but do not include contingent compensation that may not be realized. Unrealized MOIC and Unrealized IRR are metrics describing the total Fair Market Value (FMV) or “paper valuation” of the investments. This includes realized distributions already paid out and unrealized changes to a company’s valuation based upon a closed financing round and includes probability-adjusted future milestone payments. Except for realized returns, there is no assurance that any additional value can be obtained in the future. Back

Important Disclosures

Private Securities
Investments in private offerings are speculative and involve a high degree of risk. Investments in private offerings are not bank deposits and therefore are not insured by the FDIC or guaranteed by any other party. Investors must be qualified as an accredited investor to participate in private offerings and you may be required to verify your status as an accredited investor. No securities commission or regulatory authority has recommended or approved any investment or the accuracy or completeness of any of the information or materials provided by or through us.

Not Advice
This communication is not to be construed as investment, tax, or legal advice in relation to the relevant subject matter; investors must seek their own legal or other professional advice before making any investment to determine whether an investment is suitable for them.

Performance Not Guaranteed
Past performance is no guarantee of future results. Any historical returns, expected returns, or probability projections are not guaranteed and may not reflect actual future performance.

Risk of Loss
All investments involve a high degree of risk and may result in partial or total loss of your investment.

Liquidity Not Guaranteed
Investments offered by Bioverge are illiquid and there is never any guarantee that you will be able to exit your investments on the Secondary Market or at what price an exit (if any) will be achieved.

Not an Offer to Sell or Solicitation to Buy
The information presented on this Website does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Bioverge. Any such offer would only be made through of a prospectus, private placement memorandum, subscription agreement or similar documents. This Website is subject to material updating, revision and further amendment.

Conduct Your Own Due Diligence
This information is not intended to provide the sole basis for your evaluation of Bioverge. You should conduct your own due diligence of Bioverge and independently verify the information contained below before proceeding further with any investment in or other transaction with Bioverge. Our officers will make themselves available to answer any questions that you may have regarding our company, its business, operations and prospects should you decide to proceed further with an investment or other transaction with Bioverge.

Forward Looking Statements
The information set forth below includes statements, estimates, projections with respect to our anticipated future performance and other forward-looking statements, which are subject to risks, uncertainties and assumptions. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “future” or “continue”, the negative of these terms and other comparable terminology. Such forward-looking statements are based on current plans, estimates and expectations and are made pursuant to the Private Securities Litigation Reform Act of 1995. These statements, estimates and projections are based upon various assumptions that we made concerning our anticipated results and industry trends, which may or may not occur. We are not making any representations as to the accuracy of these statements, estimates or projections. Our actual performance may be materially different from the statements, estimates or projections set forth below. We are under no duty to update any of these forward-looking statements to conform them to actual results or revised expectations. Back

Diversified portfolios for investors who want streamlined exposure.

Don’t miss out on Bioverge’s next fund!

Bioverge Access Fund I

2020

0.6x

3.2x

39.2%

Bioverge Access Fund II

15 Startups • 3 Exits

2021

0.4x

2.6x

45.7%

Bioverge Access Fund III

15 Startups • 3 Exits

2022

0.1x

1.2x

8.1%

What an investment in Bioverge Funds offers you.

Access to Experience

Instant Diversification

Focus on Alpha Generation

What an investment in Bioverge Funds offers you.

Simplified Access to Premier Investments

Streamlined Diversification

Exclusive Access